logo-loader

IQ-AI subsidiary Imaging Biometrics has MRI DSC technology recognised as national standard

Published: 08:25 19 Jun 2020 BST

IQ-AI Limited - IQ-AI subsidiary Imaging Biometrics has MRI DSC technology recognised as national standard

IQ-AI Limited (LON:IQAI) said its subsidiary, Imaging Biometrics (IB), has had its MRI DSC perfusion technology, first made available through the company’s IB Neuro product, recognised as the national standard in the US for use in high-grade brain tumours.

DSC, which stands for dynamic susceptibility contrast, is the most common perfusion MRI technology used for the evaluation of brain tumours.

READ: IQ-AI climbs as subsidiary Imaging Biometrics secures grant award from National Institutes of Health

The company said the recognition was the outcome of the DSC-MRI Standardisation Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition, which provides evidence-based best practices for routine clinical use from both an MR acquisition and post-processing perspective.

“Standardising on the most common perfusion MRI technology is good news for patients and their care providers”, the company said in a statement, noting that patients diagnosed with primary brain tumours represented the “highest initial care cost for any cancer group”.

Additionally, IQ-AI chief executive Trevor Brown said the company has recommenced the process to find a buyer for its Stonechecker software, with discussions now underway with two parties.

“There is no certainty of a satisfactory conclusion of these discussions and we will update shareholders as appropriate. The Board is also exploring a new initiative in telemedicine and looking at the wider application of IB technology and products", Brown added.

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring...

on 23/2/24